North Jersey Section
American Chemical Society

Thurs Sept 21, 2023 – MSDG Vendor Show & Symposium

NJ-ACS Mass Spec Discussion Group

We’re Back!  The NJ Mass Spectrometry Discussion Group is pleased to announce the return of our Fall 2023 Annual Vendor Show and Symposium, after our pandemic hiatus.

NJ MSDG is the second largest mass spectrometry professional association in the nation behind ASMS, with over 1,100 members in the tristate area. 

Date:  Thursday,  September 21, 2023

Venue: Somerville Elks Lodge 1068
       375 Union Avenue
       Bridgewater, NJ 08807

Please  register here.  Registration is free, compliments of our sponsors.

A limited number of free drink tickets will be provided to early attendees!

Please circulate our [ flyer ].

The Vendor Show features the following sponsors / vendors / collaborators on site (listed in the order of registration):

MSDG 2023 Fall Vendor Show Sponsors


3:30 – 5:00 PM        Registration and Vendor Show

5:00 – 6:00 PM        Prof. Peter Nemes (University of Maryland)

6:00 – 7:15 PM        Buffet Dinner (raffle prizes will be announced)

7:15 – 8:15 PM        Prof. Bhagwat Prasad (Washington State University)

8:15 – 8:30 PM         Meeting Wrap-up and Close

Prof. Peter Nemes

Speaker 1: Prof. Peter Nemes

University of Maryland

“A single-cell mass spectrometry window into neurodevelopmental biology”

Abstract for Prof. Nemes:

Knowledge of all the types of molecules that are produced in cells is key to future discoveries. For example, understanding cell differentiation during early patterning of the chordate embryo and its brain regions can provide insights into the treatment of various developmental diseases. How functionally important molecules, such as proteins and metabolites, contribute to these cell processes is largely unknown. The limitation has been a lack of sufficiently sensitive mass spectrometry technologies that can measure these biomolecules with compatibility for live development, a prerequisite for functional biology. In this presentation, we will discuss the development of in situ/vivo approaches by cellular and subcellular mass spectrometry that enabled our lab to determine the proteomic and metabolomic profile of identified cells in live Xenopus laevis frog embryos developing to tadpoles and neurons in mouse brain tissues. Molecular measurements using capillary electrophoresis time-of-flight or orbitrap mass spectrometer platforms revealed proteomic and metabolomic differences between the X. laevis cells that correlated with phenotype. Follow-up functional experiments led to discoveries of molecules capable of altering normal cell fate decisions in the chordate embryo. The technology was extended to smaller cells, neurons in the mouse brain. Quantification of ~250–800 different proteins among three different types of neurons revealed reproducible proteomic differences between the neuron types. Capillary electrophoresis mass spectrometry expands the molecular toolbox of cell biology and neuroscience.

Prof. Bhagwat Prasad

Speaker 2: Prof. Bhagwat Prasad

Washington State University

“Quantitative proteomics and metabolomics in translational pharmacology and precision medicine”

Abstract for Prof. Prasad:

Drug metabolizing enzymes and transporters are critical determinants of drug absorption, metabolism, distribution, and elimination (ADME) and influence drug-drug interactions (DDIs) and response. While significant progress has been made to utilize in vitro models to predict drug ADME using physiologically-based pharmacokinetic (PBPK) models, these models require comprehensive physiological data on inter-individual variability. In particular, PBPK models require quantitative information on the levels and activity of individual pathways involved in drug disposition across different tissues and populations (healthy vs. diseased or children vs. adults). A significant lack of quantitative knowledge regarding non-Cytochrome P450 (non-CYP) enzymes and transporters in human is the major limitation towards building PBPK models in the drug development which often results inaccurate in vitro to in vivo extrapolation (IVIVE) and poor prediction of interindividual variability of drug metabolism. Although non-CYP enzymes are expressed in multiple human tissues, differential tissue expression and interindividual variability in the expression of these enzymes are not well studied. Uncharacterized sub-cellular localization of some non-CYP enzymes is another knowledge gap with respect to the development of quantitatively viable in vitro and in silico models. Similarly, animal to human scaling of non-CYP metabolism is not accurate because of the unknown inter-species differences. To address these issues, we utilize state-of-the-art quantitative proteomics in conjunction with metabolomics and genomics approaches to characterize abundances and activity of drug metabolizing enzymes and transporters in human tissues and biofluids. These data are then integrated into PBPK models to predict variability in drug clearance and DDIs, particularly in underrepresented populations such as children in whom clinical studies are not routinely performed.